Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01228513 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 263
- Enrollment target
NCT01228513 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 263 participants.
The verdict
NCT01228513, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 263 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.
Interventions
- DRUG ZK245186
- DRUG Placebo (vehicle without active ingredient)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01228513
The ClinicalTrials.gov registry entry for NCT01228513 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ZK245186 is the first listed.
NCT01228513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01228513 about?
NCT01228513 is a clinical study titled "Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)". The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.
What is the current status of trial NCT01228513?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 263 participants. The study started on 2010-11. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01228513?
The interventions under investigation include: ZK245186 (DRUG), Placebo (vehicle without active ingredient) (DRUG).
Who is sponsoring clinical trial NCT01228513?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.